Clinical Activity of Sunitinib and Regorafenib in Endometriosis

Olivier Mir, Ropert S, Stanislas Ropert, Morice P, Philippe Morice, Paul Berveiller, Berveiller P
Mayo Clinic proceedings · 2019 · vol. 94(12) , pp. 2591–2593 · doi:10.1016/j.mayocp.2019.10.001 · PMID:31806110 · W2992164093
letter OA: bronze CC0 ⤵ 2 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

This paper evaluated the clinical activity of sunitinib and regorafenib in patients with endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Antineoplastic Agents Endometriosis Gastrointestinal Stromal Tumors Ileal Neoplasms Phenylurea Compounds Pyridines Sunitinib Adult Antineoplastic Agents Endometriosis Endometriosis Endometriosis Female Gastrointestinal Stromal Tumors Gastrointestinal Stromal Tumors Humans Ileal Neoplasms Ileal Neoplasms Liver Neoplasms Liver Neoplasms

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (13)

Cited by (2)

Source provenance

europepmc
last seen: 2026-08-22T06:09:51.966504+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:22:22.912744+00:00
License: CC0 · commercial use OK